אימג'ודו - Imjudo
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01FX Other monoclonal antibodies and antibody drug conjugates |
|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | ת××-×ר××× - I.V |
| צ×רת ××× ×× | תר××× ×××× ×ª ת×××¡× ×××× ×¤××××, CONCENTRATE FOR SOLUTION FOR INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | Hepatocellular CarcinomaIMJUDO in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).Non-Small Cell Lung Cancer (NSCLC)IMJUDO in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations. |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ××××'××× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | VETTER PHARMA-FERTIGUNG GMBH & CO. KG, GERMANY |
| ×©× ××¢× ×ר×ש×× | ASTRAZENECA (ISRAEL) LTD |
| ר×ש××× | ת×ר×× ××ש×: 12/2022. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 24/07/2024 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־24 ביולי 2024 ב־18:45